This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aerie's Rhopressa Succeeds in Study on Japanese Patients
by Zacks Equity Research
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)
by Zacks Equity Research
Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Myriad Genetics (MYGN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
by Zacks Equity Research
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
A Bullish 2019 Is Here: Zacks January Market Strategy
by John Blank
This huge share price struggle is more about the clouds of policy uncertainty hanging over 2019 than it is about the present state of macro data -- or earnings, for that matter.
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
by Zacks Equity Research
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
Horizon Pharma's Ravicti Oral Liquid gets FDA approval to expand the age range to include infants younger than two months, living with a urea cycle disorder.
Myriad Genetics Posts Positive Adjusted Vectra Test Data
by Zacks Equity Research
The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
by Zacks Equity Research
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
U.S. Political Tumult Shrouds Markets: 5 Safe Picks
by Tirthankar Chakraborty
Trump's continuous bashing of the Fed and Treasury Secretary Steven Mnuchin's phone calls to major banks to assess their financial health have been unnerving investors.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) see strong testing volumes from new products.
Myriad Genetics Announces Encouraging EndoPredict Test Data
by Zacks Equity Research
Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.
Myriad (MYGN) Down 3.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Quality Stocks to Counter Market Volatility
by Zacks Equity Research
With the markets currently facing a lot of gyration, investing in quality stocks seems prudent. After all, these stocks provide excellent risk-adjusted returns.
Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag
by Zacks Equity Research
Myriad Genetics (MYGN) witnesses strong performance by GeneSight, EndoPredict, and Prolaris tests in Q1.
Myriad Genetics (MYGN) Beats Q1 Earnings Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 43.33% and -0.80%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Why the Earnings Surprise Streak Could Continue for Myriad (MYGN)
by Zacks Equity Research
Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Myriad Genetics (MYGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?
by Zacks Equity Research
Improvement in prescriptions growth rate of SUBSYS and SYNDROS to drive INSYS Therapeutics' (INSY) Q3 earnings.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Strong domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets likely to drive Tandem Diabetes' (TNDM) Q3 earnings.
What's in Store for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.